Rhabdomyosarcoma-Pipeline Review, H1 2017

Rhabdomyosarcoma-Pipeline Review, H1 2017


  • Products Id :- GMDHC9209IDB
  • |
  • Pages: 177
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Rhabdomyosarcoma-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma-Pipeline Review, H1 2017, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 6, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rhabdomyosarcoma-Overview 6

Rhabdomyosarcoma-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Rhabdomyosarcoma-Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 17

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Rhabdomyosarcoma-Companies Involved in Therapeutics Development 24

Bellicum Pharmaceuticals Inc 24

Boehringer Ingelheim GmbH 24

Bristol-Myers Squibb Company 25

Celgene Corp 25

CytRx Corp 26

EpiZyme Inc 26

Exelixis Inc 27

Iproteos SL 27

Ipsen SA 28

MacroGenics Inc 28

Novartis AG 29

Noxxon Pharma AG 29

Pfizer Inc 30

Shionogi & Co Ltd 30

Taiho Pharmaceutical Co Ltd 31

Rhabdomyosarcoma-Drug Profiles 32

afatinib dimaleate-Drug Profile 32

aldoxorubicin hydrochloride-Drug Profile 46

AT-69-Drug Profile 61

axitinib-Drug Profile 62

cabozantinib s-malate-Drug Profile 68

Cellular Immunotherapy for GD2 Expressing Solid Tumors-Drug Profile 87

Cellular Immunotherapy for Oncology-Drug Profile 89

Cellular Immunotherapy to Target GD2 and CD56 for Solid Tumors-Drug Profile 91

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 92

Celyvir-Drug Profile 93

crizotinib-Drug Profile 94

enoblituzumab-Drug Profile 101

everolimus-Drug Profile 104

ipilimumab + nivolumab-Drug Profile 118

irinotecan hydrochloride-Drug Profile 123

MAL-3101-Drug Profile 135

NOXS-93-Drug Profile 136

NR-001-Drug Profile 137

paclitaxel albumin bound-Drug Profile 138

pazopanib hydrochloride-Drug Profile 150

S-588410-Drug Profile 158

Synthetic Peptides for Rhabdomyosarcoma-Drug Profile 160

TAS-4464-Drug Profile 161

tazemetostat-Drug Profile 162

VIMO-001-Drug Profile 171

Rhabdomyosarcoma-Dormant Projects 172

Rhabdomyosarcoma-Discontinued Products 173

Appendix 174

Methodology 174

Coverage 174

Secondary Research 174

Primary Research 174

Expert Panel Validation 174

Contact Us 174

Disclaimer 175

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Rhabdomyosarcoma-Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Rhabdomyosarcoma-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Rhabdomyosarcoma-Pipeline by Bristol-Myers Squibb Company, H1 2017

Rhabdomyosarcoma-Pipeline by Celgene Corp, H1 2017

Rhabdomyosarcoma-Pipeline by CytRx Corp, H1 2017

Rhabdomyosarcoma-Pipeline by EpiZyme Inc, H1 2017

Rhabdomyosarcoma-Pipeline by Exelixis Inc, H1 2017

Rhabdomyosarcoma-Pipeline by Iproteos SL, H1 2017

Rhabdomyosarcoma-Pipeline by Ipsen SA, H1 2017

Rhabdomyosarcoma-Pipeline by MacroGenics Inc, H1 2017

Rhabdomyosarcoma-Pipeline by Novartis AG, H1 2017

Rhabdomyosarcoma-Pipeline by Noxxon Pharma AG, H1 2017

Rhabdomyosarcoma-Pipeline by Pfizer Inc, H1 2017

Rhabdomyosarcoma-Pipeline by Shionogi & Co Ltd, H1 2017

Rhabdomyosarcoma-Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Rhabdomyosarcoma-Dormant Projects, H1 2017

Rhabdomyosarcoma-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bellicum Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, CytRx Corp, EpiZyme Inc, Exelixis Inc, Iproteos SL, Ipsen SA, MacroGenics Inc, Novartis AG, Noxxon Pharma AG, Pfizer Inc, Shionogi & Co Ltd, Taiho Pharmaceutical Co Ltd

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com